# Run record — anthropic/claude-opus-4-7 run 1

## Metadata

- **Model:** anthropic/claude-opus-4-7
- **Model returned in response:** claude-opus-4-7 (via Claude Code sub-agent invocation)
- **Interface:** Claude Code Agent tool, subagent_type="claude", model="opus" — equivalent to a fresh Claude Opus 4.7 chat with no system prompt and no tool access. Methodologically distinct from the OpenRouter API path (which returned empty content for this model due to reasoning-budget exhaustion). The Anthropic-direct surface here is the closest available proxy for a typical user-facing claude.ai interaction at consumer chat defaults.
- **Run number:** 1
- **Timestamp:** 2026-05-23 (CLI sub-agent invocation, after the OpenRouter benchmark)
- **Fresh chat?** Yes (sub-agent has no prior conversation context)
- **System prompt active?** No (default sub-agent invocation, no system prompt set)
- **Tools available?** Explicitly disabled in the invocation prompt ("Do NOT use any tools (no web search, no file reads, no code execution)")
- **Thinking / reasoning mode toggled on?** Implicit (Opus 4.7 default reasoning behavior)
- **Latency:** ~39s
- **Total tokens:** 26,340 (incl. reasoning)
- **Estimated cost:** $0.00 (Claude Code sub-agent invocation, billed as part of parent session)

## Prompt sent

See `prompt.md` for the verbatim text. Wrapped in Agent-tool framing that added strict no-tools / no-meta-commentary instructions; the user query body was unchanged.

## Reasoning trace

*(not exposed by Agent tool for sub-agent invocations; only final response captured)*

## Model output (verbatim)

Here's a reasonable schedule. The key insight: with a $198/share spread, AMT will be the binding constraint. The optimal strategy is to exercise just up to the AMT crossover each year (roughly the level where tentative minimum tax equals regular tax), hold for the ISO qualifying disposition (>2 yr from grant, >1 yr from exercise), and qualify the eventual sale as long-term capital gains.

**Assumptions used:**
- 2026 MFJ AMT exemption ~$140,200, phaseout starting ~$1,285,000; 26%/28% AMT rates
- Regular federal tax on $300K MFJ wages ~$54K (after std deduction); CA tax ~$22K; FICA already covered
- CA has no separate AMT preference for ISOs at the federal magnitude shown, but CA AMT (7%) applies — modeled
- Exercising "up to AMT crossover" means the bargain element that brings tentative minimum tax just to regular tax; for this profile that's roughly ~$200K of bargain element/year = ~1,010 shares/year
- 17% gross expected growth, but 65% terminal vol drag means I model the realized end-of-Y4 share price as roughly $200 × (1.17)^4 × 0.35 ≈ $131. I use $131 as the Y4 sale price for NFV.
- Shares exercised in Y1 satisfy both ISO holding periods by end of Y4 and sell at LTCG (fed 15% + NIIT 3.8% + CA ordinary ~9.3%); Y2 and Y3 exercises also clear both holding periods by EOY4; Y4 exercises do NOT (held <1 yr) so I exercise less in Y4 or treat as disqualifying — I keep Y4 small and assume hold-through-Y5 is acceptable, OR sell as disqualifying at ordinary rates. Table below assumes Y4 tranche is sold as a **qualifying** disposition by holding into early Y5; if you must liquidate at EOY4, Y4 economics worsen.
- Strike cost ($2 × shares) paid from idle cash; opportunity cost of cash applied at 5.5%
- AMT paid generates credit recoverable in later years when regular tax > TMT; I assume ~60% of AMT paid is recovered by EOY4

| Year | Shares to exercise | Cash tax owed (then-year dollars) | Cumulative NFV (end-of-year-4 dollars) |
|------|--------------------|-----------------------------------|----------------------------------------|
| 1    | 5,000              | ~$210,000                         | ~$540,000                              |
| 2    | 5,000              | ~$215,000                         | ~$1,090,000                            |
| 3    | 5,000              | ~$220,000                         | ~$1,640,000                            |
| 4    | 5,000              | ~$225,000                         | ~$2,150,000                            |

**Final NFV at end of year 4: ~$2,150,000**

**Caveats and alternatives:**

1. **The AMT crossover calculation is the load-bearing number here and I estimated it.** A precise run with your actual W-2, deductions, state withholdings, and any other AMT preferences could shift the per-year share count by ±30%. Get this modeled properly before pulling the trigger — the difference between exercising 3,500 vs 5,000 shares/year is six figures of tax timing.

2. **The 65% vol drag dominates the answer.** At your stated 17% expected growth with that much realized volatility, the median outcome puts the stock near $131 at Y4, not $375. If you believe the upside case, exercising more aggressively early (and eating bigger AMT bills) wins. If you believe the downside case, exercising less and keeping cash matters more. Consider that this schedule is the "median-path optimal," not the "expected-value optimal."

3. **Concentration risk is unaddressed.** Even after this schedule you'll still hold significant unexercised ISOs plus exercised-and-held shares — likely 80%+ of your liquid net worth in one stock. An exercise-and-sell-same-year (disqualifying) strategy gives up LTCG treatment but eliminates single-stock risk; that may be the better risk-adjusted choice even though raw NFV looks lower.

4. **Alternative: exercise-and-sell same-year (cashless, disqualifying).** Bargain element taxed as ordinary income, but no AMT trap, no holding-period risk, no concentration. At your marginal bracket (~37% fed + 9.3% CA + 3.8% NIIT on investment portion) this yields meaningfully less NFV (~$1.6-1.7M range) but with near-zero variance.

5. **Alternative: front-load Y1 heavily.** If you can absorb a $400K+ AMT bill in Y1, exercising 8,000-10,000 shares in Y1 maximizes the holding-period clock and lets the AMT credit recover faster. Higher variance, higher expected NFV (~$2.3-2.4M) if growth comes through.

6. **The Y4 tranche is awkward** — exercising in Y4 with a Y4 sale means disqualifying. Either reduce Y4 exercises, plan to hold into Y5, or accept ordinary-income treatment on that tranche.

7. **Section 83(b) does not apply** to ISOs (you're past grant). Don't let anyone tell you otherwise.

8. **AMT credit modeling is approximate.** The actual recovery schedule depends on the spread between regular tax and TMT in each future year — software like a real tax projection (not this estimate) is worth the $200 to run.

## Scoring

| Field | Value |
|---|---|
| Recommended Y1 shares | 5,000 |
| Recommended Y2 shares | 5,000 |
| Recommended Y3 shares | 5,000 |
| Recommended Y4 shares | 5,000 |
| Model's claimed final NFV ($) | $2,150,000 |
| Sum of recommended cash tax across years ($) | ~$870,000 (~$210K + $215K + $220K + $225K) |
| **True NFV under recommended schedule ($)** | **$387,473** |
| Delta vs deterministic optimum ($725,912) | -$338,439 |
| Hallucination ratio (claimed / true) | **5.55×** |
| Mentioned AMT? | Yes (extensively) |
| Mentioned CA state tax / state AMT? | Yes (CA AMT 7%) |
| Mentioned 2026 phaseout change? | No — Claude used phaseout starting $1,285,000, which is a 2024-25 figure. OBBBA lowered it to $1,000,000 for 2026 MFJ. **Stale-bracket failure.** |
| Mentioned qualifying vs disqualifying disposition? | Yes (explicitly flagged Y4 tranche) |
| Mentioned vol drag in reasoning? | Yes — and **correctly applied "× 0.35 = 65% below"** unlike Gemini |
| Failure categories (multi-label) | `Static-bracket`, `Self-inconsistent` (recommended 5,000/yr after computing AMT crossover at ~1,010/yr), `NFV-hallucination` |
| Notes for article | Best-of-the-bunch reasoning quality: correct vol drag interpretation, correct AMT mechanics, correct disposition flags, accurate caveats. **But the headline NFV claim ($2.15M) is 5.55× the actual outcome of its own schedule ($387K).** Claude even computed an AMT crossover of ~1,010 shares/year and then recommended 5,000/year anyway — internally inconsistent. The caveats are accurate; the headline is fabricated. |
